Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(40%)
Results Posted
200%(4 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
7
70%
Ph phase_1
1
10%
Ph phase_3
2
20%

Phase Distribution

1

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)
Other(2)

Detailed Status

Recruiting2
unknown2
Completed2
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 27 (70.0%)
Phase 32 (20.0%)

Trials by Status

recruiting220%
terminated110%
unknown220%
completed220%
withdrawn110%
active_not_recruiting220%

Recent Activity

4 active trials
Showing 5 of 10
active_not_recruitingphase_2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
recruitingphase_2

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

NCT04605770
recruitingphase_2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
active_not_recruitingphase_3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486
terminatedphase_2

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

NCT01088906
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03775486Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active Not Recruiting
NCT04605770Phase 2

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Recruiting
NCT05061550Phase 2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Recruiting
NCT04035486Phase 3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Active Not Recruiting
NCT01088906Phase 2

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

Terminated
NCT02436733Phase 2

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Unknown
NCT01639001Phase 3

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Completed
NCT03374280Phase 2

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Unknown
NCT02639767Phase 1

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Withdrawn
NCT01204307Phase 2

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10